REFERENCES

1. Sadock BJ, Sadock VA, Kaplan HI. Kaplan and Sadock's concise textbook of child and adolescent psychiatry. Lippincott Williams and Wilkins; 2009.
2. American Diabetes Association. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes care. 2004 Feb 1; 27(2):596-601.
3. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl j Med. 2005 Sep 22; 2005(353):1209-23.
4. Paton C, Esop R, Young C, Taylor D. Obesity, dyslipidaemias and smoking in an inpatient population treated with antipsychotic drugs. Acta Psychiatrica Scandinavica. 2004 Oct 1; 110(4):299-305.
5. Saari K, Jokelainen J, Veijola J, Koponen H, Jones PB, Savolainen M, Järvelin MR, Lauren L, Isohanni M, Lindeman S. Serum lipids in schizophrenia and other functional psychoses: a general population northern Finland 1966 birth cohort survey. Acta Psychiatrica Scandinavica. 2004 Oct 1; 110(4):279-85.
6. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects. CNS drugs. 2005 Dec 1; 19(1):1-93.
7. Kaddurah-Daouk R, McEvoy J, Baillie R, Zhu H, Yao JK, Nimgaonkar VL, Buckley PF, Keshavan MS, Georgiades A, Nasrallah HA. Impaired plasmalogens in patients with schizophrenia. Psychiatry research. 2012 Aug 15; 198(3):347-52.
8. Schwarz E, Prabakaran S, Whitfield P, Major H, Leweke FM, Koethe D, McKenna P, Bahn S. High throughput lipidomic profiling of schizophrenia and bipolar disorder brain tissue reveals alterations of free fatty acids, phosphatidylcholines, and ceramides. Journal of proteome research. 2008 Sep 9;7(10):4266-77.
9. Thakore JH. Metabolic disturbance in first-episode schizophrenia. The British Journal of Psychiatry. 2004 Apr 1; 184(47):s76-9.
10. Verma SK, Subramaniam M, Liew A, Poon LY. Metabolic risk factors in drug-naive patients with first-episode psychosis. The Journal of clinical psychiatry. 2009 Jul; 70(7):997-1000.
11. Mahadik SP, Evans DR. Is schizophrenia a metabolic brain disorder? Membrane phospholipid dysregulation and its therapeutic implications. Psychiatric Clinics. 2003 Mar 1; 26(1):85-102.
12. Bentsen H, Solberg DK, Refsum H, Gran JM, Bøhmer T, Torjesen PA, Halvorsen O, Lingjærde O. Bimodal distribution of polyunsaturated fatty acids in schizophrenia suggests two endophenotypes of the disorder. Biological psychiatry. 2011 Jul 1; 70(1):97-105.
13. Hoen WP, Lijmer JG, Duran M, Wanders RJ, van Beveren NJ, de Haan L. Red blood cell polyunsaturated fatty acids measured in red blood cells and schizophrenia: a meta-analysis. Psychiatry research. 2013 May 15; 207(1):1-2.
14. Khan MM, Evans DR, Gunna V, Scheffer RE, Parikh VV, Mahadik SP. Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophrenia research. 2002 Nov 1; 58(1):1-0.
15. Montesinos-Rueda L, Canete-Crespillo J, Palma-Sevillano C, Gine-Serven E. Erythrocyte membrane polyunsaturated fatty acid (pufa) levels in a sample of patients with schizophrenia and relation with clinical and progression variables. Actas Esp Psiquiatr. 2015 Sep 1; 43(5):170-6.
16. Van der Kemp WJ, Klomp DW, Kahn RS, Luijten PR, Pol HH. A meta-analysis of the polyunsaturated fatty acid composition of erythrocyte membranes in schizophrenia. Schizophrenia research. 2012 Nov 30; 141(2):153-61.
17. Wahlbeck K, Tuunainen A, Ahokas A, Leucht S. Dropout rates in randomised antipsychotic drug trials. Psychopharmacology. 2001 May 1; 155(3):230-3.
18. Phelan M, Stradins L, Morrison S. Physical health of people with severe mental illness: can be improved if primary care and mental health professionals pay attention to it. BMJ: British Medical Journal. 2001 Feb 24; 322(7284):443.
19. Kakafika AI, Liberopoulos EN, Karagiannis A, Athyros VG, Mikhailidis DP. Dyslipidaemia, hypercoagulability and the metabolic syndrome. Current vascular pharmacology. 2006 Jul 1; 4(3):175-83.
20. Barnett AH, Mackin P, Chaudhry I, Farooqi A, Gadsby R, Heald A, Hill J, Millar H, Peveler R, Rees A, Singh V. Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia. Journal of Psychopharmacology. 2007 Jun; 21(4):357-73.
21. Birkenaes AB, Birkeland KI, Engh JA, Færden A, Jonsdottir H, Ringen PA, Friis S, Opjordsmoen S, Andreassen OA. Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions. Journal of clinical psychopharmacology. 2008 Apr 1; 28(2):132-7.
22. Chiu CC, Chen CH, Chen BY, Yu SH, Lu ML. The time-dependent change of insulin secretion in schizophrenic patients treated with olanzapine. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2010 Aug 16; 34(6):866-70.
23. Medved V, Kuzman MR, Jovanovic N, Grubisin J, Kuzman T. Metabolic syndrome in female patients with schizophrenia treated with second generation antipsychotics: a 3-month follow-up. Journal of psychopharmacology. 2009 Nov; 23(8):915-22.
24. Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophrenia research. 2004 Sep 1; 70(1):1-7.
25. Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. American Journal of Psychiatry. 2003 Feb 1; 160(2):284-9.
26. Sengupta S, Parrilla-Escobar MA, Klink R, Fathalli F, Ng YK, Stip E, Baptista T, Malla A, Joober R. Are metabolic indices different between drug-naïve first-episode psychosis patients and healthy controls?. Schizophrenia research. 2008 Jul 31; 102(1):329-36.
27. Grover S, Aggarwal M, Dutt A, Chakrabarti S, Avasthi A, Kulhara P, Somaiya M, Malhotra N, Chauhan N. Prevalence of metabolic syndrome in patients with schizophrenia in India. Psychiatry research. 2012 Dec 30; 200(2):1035-7.
28. Perez-Iglesias R, Crespo-Facorro B, Amado JA, Garcia-Unzueta MT, Ramirez-Bonilla ML, Gonzalez-Blanch C, Martinez-Garcia O, Vazquez-Barquero JL. A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone. The Journal of clinical psychiatry. 2007 Nov; 68(11):1733-40.
29. Saari K, Koponen H, Laitinen J, Jokelainen J, Lauren L, Isohanni M, Lindeman S. Hyperlipidemia in persons using antipsychotic medication: a general population-based birth cohort study. The Journal of clinical psychiatry. 2004 Apr; 65(4):547-50.
30. Sheitman BB, Bird PM, Binz W, Akinli L, Sanchez C. Olanzapine-induced elevation of plasma triglyceride levels. American Journal of Psychiatry. 1999 Sep 1; 156(9):1471-a.
31. Tarricone I, Casoria M, Gozzi BF, Grieco D, Menchetti M, Serretti A, Ujkaj M, Pastorelli F, Berardi D. Metabolic risk factor profile associated with use of second generation antipsychotics: a cross sectional study in a Community Mental Health Centre. BMC psychiatry. 2006 Mar 16; 6(1):11.
32. Gupta S, Steinmeyer C, Frank B, Madhusoodanan S, Lockwood K, Lentz B, Keller P. Hyperglycemia and hypertriglyceridemia in real world patients on antipsychotic therapy. American journal of therapeutics. 2003 Sep 1; 10(5):348-55.
33. Vancampfort D, Wampers M, Mitchell AJ, Correll CU, Herdt A, Probst M, Hert M. A meta‐analysis of cardio‐metabolic abnormalities in drug naïve, first‐episode and multi‐episode patients with schizophrenia versus general population controls. World Psychiatry. 2013 Oct 1; 12(3):240-50.
34. Mitchell AJ, Vancampfort D, De Herdt A, Yu W, De Hert M. Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients. Schizophrenia bulletin. 2012 Aug 27; 39(2):295-305.